Arovella Therapeutics Ltd has released a press release.
Arovellas OroMist R&D facility closure completed
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- Response to ASX Query
- Response to ASX Aware Query
- ALA-101 confers survival benefit in leukemia model
- Arovella completes $1.65M placement
- R&D Tax Incentive refund received
Later from Arovella Therapeutics
- Arovella completes $4M placement & launches $1M spp
- Share Purchase Plan (SPP) Offer Booklet
- Share Purchase Plan (SPP) Closing Date Extended
- Completion of oversubscribed Share Purchase Plan (SPP)
- Quarterly Appendix 4C and Activities Report
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics